Early trial results show benefits of FGFR inhibitors and PARP/ATR inhibitor combinations in multiple tumor types

by

Researchers from The University of Texas MD Anderson Cancer Center presented promising findings from multiple clinical trials today at the American Association for Cancer Research (AACR) Annual Meeting 2023.

Leave A Comment

Your email address will not be published. Required fields are marked *